A study to evaluate LTI-03 in patients with Idiopathic Pulmonary Fibrosis

• Research type

  Research Study

• Full title

  A Randomized, Double-Blind, Placebo-Controlled, Phase 1b, Dose Escalation, Safety, Tolerability and Pharmacodynamic Biomarker Study of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Recently Diagnosed, Treatment Naïve Subjects with Idiopathic Pulmonary Fibrosis

• IRAS ID

  1006203

• Contact name

  Philip Molyneaux

• Contact email

  p.molyneaux@rbht.nhs.uk

• Sponsor organisation

  Lung Therapeutics Inc.

• Eudract number

  2022-000083-21

• Clinicaltrials.gov Identifier

  NCT05954988

• Research summary

  This is a randomized, double-blind, placebo-controlled, multi-center, dose escalation, safety, and tolerability study of LTI-03 or placebo administered by inhalation in recently diagnosed subjects with IPF without prior treatment with anti-fibrotic agents. In total, approximately 24 subjects will be randomized in the study.

• REC name

  South Central - Oxford A Research Ethics Committee

• REC reference

  22/SC/0289

• Date of REC Opinion

  8 Nov 2022

• REC opinion

  Further Information Favourable Opinion